Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

Published:2020-01-01 Issue:1 Volume:156 Page:44
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Simpson Eric L.¹,Paller Amy S.²³,Siegfried Elaine C.⁴,Boguniewicz Mark⁵,Sher Lawrence⁶,Gooderham Melinda J.⁷⁸⁹,Beck Lisa A.¹⁰,Guttman-Yassky Emma¹¹¹²¹³,Pariser David¹⁴,Blauvelt Andrew¹⁵,Weisman Jamie¹⁶,Lockshin Benjamin¹⁷¹⁸,Hultsch Thomas¹⁹,Zhang Qin²⁰,Kamal Mohamed A.²⁰,Davis John D.²⁰,Akinlade Bolanle²⁰,Staudinger Heribert²¹,Hamilton Jennifer D.²⁰,Graham Neil M. H.²⁰,Pirozzi Gianluca²¹,Gadkari Abhijit²⁰,Eckert Laurent²²,Stahl Neil²⁰,Yancopoulos George D.²⁰,Ruddy Marcella²⁰,Bansal Ashish²⁰

Affiliation:

1. Department of Dermatology, Oregon Health & Science University, Portland

2. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

3. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois

4. Department of Pediatrics, School of Medicine, Saint Louis University, St. Louis, Missouri

5. Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver

6. Peninsula Research Associates, Rolling Hills Estates, California

7. Skin Centre for Dermatology, Peterborough, Ontario, Canada

8. Department of Medicine, Queen's University, Kingston, Ontario, Canada

9. Probity Medical Research, Waterloo, Ontario, Canada

10. Department of Dermatology, University of Rochester Medical Center, Rochester, New York

11. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

12. Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York

13. Laboratory for Investigative Dermatology, Rockefeller University, New York, New York

14. Department of Dermatology, Eastern Virginia Medical School, Norfolk

15. Oregon Medical Research Center, Portland

16. Advanced Medical Research, Atlanta, Georgia

17. US Dermatology Partners, Rockville, Maryland

18. Georgetown University, Washington, District of Columbia

19. Sanofi Genzyme, Cambridge, Massachusetts

20. Regeneron Pharmaceuticals Inc, Tarrytown, New York

21. Sanofi, Bridgewater, New Jersey

22. Sanofi, Chilly-Mazarin, France

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2753673/jamadermatology_simpson_2019_oi_190057.pdf

Reference43 articles.

1. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder.;Brunner;J Invest Dermatol,2017

2. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases.;Shrestha;Adv Ther,2017

3. Major comorbidities of atopic dermatitis: beyond allergic disorders.;Paller;Am J Clin Dermatol,2018

4. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health.;Shaw;J Invest Dermatol,2011

5. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.;Odhiambo;J Allergy Clin Immunol,2009

Cited by 355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China;Journal of Medical Economics;2024-09-13

2. Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years;Frontiers in Pediatrics;2024-09-04

3. Atopic dermatitis and IgE-mediated food allergy;Annals of Allergy, Asthma & Immunology;2024-09

4. Current and Emerging Biologics for Atopic Dermatitis;Immunology and Allergy Clinics of North America;2024-09

5. Prevention of Atopic Dermatitis in Children: Can It be Done?;Current Dermatology Reports;2024-08-26